Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 12/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.38 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.37 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL75787 | 0.86 | KDM1A (0.39) | MAOAMAOB | |
| SCHEMBL8556517 | 0.82 | SIGMAR1 (0.39) | SIGMAR1ADRA2AMAOAMAOB | |
| SCHEMBL8554610 | 0.82 | SIGMAR1 (0.39) | SIGMAR1ADRA2AMAOAMAOB | |
| SCHEMBL5326427 | 0.79 | MME (0.38) | SIGMAR1MAOAMAOB | |
| SCHEMBL7918041 | 0.78 | S1PR1 (0.48) | S1PR1KCNH2S1PR5 | |
| SCHEMBL21899583 | 0.78 | S1PR1 (0.46) | S1PR1KCNH2S1PR5 | |
| SCHEMBL16605576 | 0.78 | S1PR1 (0.43) | S1PR1KCNH2S1PR5 | |
| SCHEMBL7919829 | 0.78 | S1PR1 (0.46) | S1PR1KCNH2S1PR5 | |
| SCHEMBL9583897 | 0.77 | SIGMAR1 (0.39) | SIGMAR1ADRA2AMAOAMAOB | |
| SCHEMBL7923890 | 0.76 | S1PR1 (0.35) | S1PR1KCNH2S1PR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9315492-B2 | Heterocyclic group contained amino-methanol derivative, and salt, synthetic method and use thereof | BEIJING FORELAND BIOPHARMA CO., LTD. (CN) | 2016-04-19 | — | — | US | disclosed |
| CN-104583187-A | Heterocyclic group-containing amino methanol derivative and salt thereof, and synthesis method and application thereof | BEIJING FORELAND BIOPHARMA CO LTD | 2015-04-29 | — | — | CN | disclosed |
| US-20150094337-A1 | HETEROCYCLIC GROUP CONTAINED AMINO-METHANOL DERIVATIVE, AND SALT, SYNTHETIC METHOD AND USE THEREOF | BEIJING FORELAND BIOPHARMA CO., LTD. (CN) | 2015-04-02 | — | — | US | disclosed |
| US-8569312-B2 | Biaryl-spiroaminooxzaoline analogues as alpha 2C adrenergic receptor modulators | MERCK SHARP & DOHME CORP. (US) | 2013-10-29 | — | — | US | disclosed |
| US-20130225582-A1 | BIARYL-SPIROAMINOOXZAOLINE ANALOGUES AS ALPHA 2C ADRENERGIC RECEPTOR MODULATORS | MERCK SHARP & DOHME CORP. (US) | 2013-08-29 | — | — | US | disclosed |
| US-8476274-B2 | Biaryl spiroaminooxazoline analogues as Alpha2C adrenergic receptor modulators | MERCK SHARP & DOHME CORP. (US) | 2013-07-02 | — | — | US | disclosed |
| US-20130045914-A1 | BIARYL SPIROAMINOOXAZOLINE ANALOGUES AS ALPHA2C ADRENERGIC RECEPTOR MODULATORS | MERCK SHARP & DOHME CORP (US) | 2013-02-21 | — | — | US | disclosed |
| US-8324213-B2 | Biaryl-spiroaminooxazoline analogues as alpha 2C adrenergic receptor modulators | MERCK SHARP & DOHME CORP. (US) | 2012-12-04 | — | — | US | disclosed |
| US-20110251207-A1 | BIARYL-SPIROAMINOOXAZOLINE ANALOGUES AS ALPHA 2C ADRENERGIC RECEPTOR MODULATORS | MERCK SHARP & DOHME CORP. (US) | 2011-10-13 | — | — | US | disclosed |
| EP-0635497-B1 | Benzospiroalkene derivatives, process for their preparation and pharmaceutical compostions containing them | ADIR (FR) | 1998-05-20 | — | — | EP | disclosed |
| EP-0635497-A2 | Benzospiroalkene derivatives, process for their preparation and pharmaceutical compostions containing them | ADIR ET COMPAGNIE (FR) | 1995-01-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150094337-A1 | HETEROCYCLIC GROUP CONTAINED AMINO-METHANOL DERIVATIVE, AND SALT, SYNTHETIC METHOD AND USE THEREOF | SSB, HLA-DRB1, MYD88 | S1PR1 482/4885KCNH2 2295/4885SIGMAR1 2520/4885 |
| US-20130225582-A1 | BIARYL-SPIROAMINOOXZAOLINE ANALOGUES AS ALPHA 2C ADRENERGIC RECEPTOR MODULATORS | ADRA2C, ADRB2, ADRA2A | S1PR1 401/4885KCNH2 884/4885SIGMAR1 111/4885 |
| US-20130045914-A1 | BIARYL SPIROAMINOOXAZOLINE ANALOGUES AS ALPHA2C ADRENERGIC RECEPTOR MODULATORS | ADRA2C, ADRB2, ADRA2A | S1PR1 468/4885KCNH2 1142/4885SIGMAR1 136/4885 |
| US-20110251207-A1 | BIARYL-SPIROAMINOOXAZOLINE ANALOGUES AS ALPHA 2C ADRENERGIC RECEPTOR MODULATORS | ADRA2C, ADRB2, ADRB3 | S1PR1 402/4885KCNH2 1348/4885SIGMAR1 108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.